The global Nuclear Medicine Market size was valued at USD 8,586.5 million in 2023 and is projected to reach USD 19,840.0 million by 2031, growing at a CAGR of 11.16% from 2024 to 2031. The rising incidence of cardiovascular disease, neurological disorders, and cancer, among others is expected to drive market growth.

The growing prevalence of neurological conditions, cancer, and cardiovascular disease, among other illnesses, is anticipated to propel market expansion. The growing trend of AI-powered personalized healthcare is driving demand for new solutions and will drive market growth in the years to come. 

𝐀𝐜𝐞𝐬𝐬 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨 @ https://www.kingsresearch.com/nuclear-medicine-market-721

Key Industry Developments: 

April 2024 (Agreement): Novartis Innovative Therapies AG announced the finalization of an amended and restated licensing agreement with 3B Pharmaceuticals GmbH (3BP) due to their innovative fibroblast activation protein (FAP)-targeting peptide technology. The key focus of this agreement was on FAP-2286, a clinical candidate specifically designed to target FAP, a promising therapeutic target exhibiting widespread expression across various cancer types.

List of Key Companies in Nuclear Medicine Market: Siemens Healthineers AG, Novartis AG, Curium Pharma, Cambridge Isotope Laboratories, Cardinal Health, GE Healthcare, Nordion, Merck KGaA, Lantheus Holdings, Bracco S.p.A

Asia-Pacific is estimated to experience significant growth at a CAGR of 13.79% over the forecast period. The region is witnessing a notable rise in disposable incomes, which is resulting in increased access to healthcare services, including advanced imaging diagnostics such as nuclear medicine. As the region continues to grow economically and technologically, there is a growing demand for advanced imaging technologies, including nuclear medicine.

Moreover, ongoing technological advancements in nuclear imaging systems, radiopharmaceuticals, and data analysis tools are enhancing the accuracy, efficiency, and safety of nuclear medicine procedures in the Asia-Pacific region. These advancements are anticipated to improve patient care by expanding the clinical applications of nuclear medicine and fostering investment in the region's healthcare infrastructure.

Key Drivers of Market Growth:

Rising Prevalence of Chronic Diseases: The increasing incidence of cardiovascular diseases, neurological disorders, and cancers is a significant driver of the nuclear medicine market. These conditions often require advanced diagnostic imaging techniques for accurate diagnosis and treatment planning.

Technological Advancements: The development of high-resolution imaging modalities and the integration of artificial intelligence in diagnostic procedures are enhancing the precision and efficiency of nuclear medicine. Innovations in PET and SPECT technologies are particularly noteworthy, providing detailed insights into metabolic activities and improving early disease detection.

Regional Insights:

North America: North America dominates the nuclear medicine market, driven by advanced healthcare infrastructure, significant research activities, and high healthcare expenditure. The presence of key market players and increasing awareness about the benefits of nuclear medicine are also contributing factors.

Europe: Europe holds a substantial share of the market, with growing investments in healthcare technology and a focus on early disease detection. Countries like Germany, France, and the UK are at the forefront, leveraging advanced imaging techniques to improve patient outcomes.

Nuclear Medicine Market is Segmented:

By Product-

Diagnostic

Therapeutic

By Application-

Cardiology

Neurology

Oncology

Thyroid

Lymphoma

Bone Metastasis

Endocrine Tumor

Others

By End-user-

Hospitals & Clinics

Diagnostics Centers

Others

Contact us:
Kings Research
Website: https://www.kingsresearch.com
E-mail: business@kingsresearch.com
Phone: (+1) 888 328 2189